The Latest Developments in Oncology Research

Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

Included in this Trendline:

  • AstraZeneca, Daiichi drug approved by FDA in breast cancer first
  • GSK to pull blood cancer drug from US market after study failure
  • Amgen data supports KRAS cancer drug, but survival benefit remains in question

Request Free!